THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES. (June 2017) - Hamlin, P.A.; Farber, C.M.; Fenske, T.S.; Khatcheressian, J.L.; Miller, C.B.; Munoz, J.; Patel, M.R.; Schreeder, M.T.; Smith, S.M.; Stevens, D.A.; Pandey, A.; Birrell, M.R.; et al.